After the attention-grabbing results at ASCO 2026, researchers are extending the testing of amivantamab to the third clinical phase, while expectations for this treatment are growing significantly

A new cancer treatment is considered one of the most promising developments in recent years in oncology, after the results of a clinical trial showed that in some patients the tumors completely disappeared.

It is about amivantamab, a dual-acting therapy against the EGFR and MET receptors, is being tested in patients with advanced head and neck cancer whose disease had returned or was no longer responding to standard treatments.

According to data reported by The Guardian and presented at ASCO 2026, 102 patients participated in the OrigAMI-4 study. The results showed that 42 percent of them had a response to the treatment, while 15 percent reported complete disappearance of the tumor.

Experts consider this an extremely important result, especially for patients with aggressive forms of the disease, who usually have very few therapeutic options after the cancer progresses after chemotherapy or immunotherapy, Telegrafi reports.

Amivantamab works by blocking two important pathways that help the growth and spread of tumor, while simultaneously helping the immune system to recognize and attack cancer cells. This combined approach is the reason why the therapy is attracting so much attention in the scientific community.

Another important development is that the third phase study, OrigAMI-5, has already started, which will test this therapy in a larger group of patients and at an earlier stage of treatment. This phase is considered crucial to understand whether the results can be confirmed on a larger scale.

Although the data are very encouraging, the researchers emphasize that more extensive trials and longer follow-up of patients are still needed to assess the long-term benefit, safety and the possibility of wider clinical use.

Currently, the results are being seen as an important step for patients with advanced head and neck cancer, but also as a signal of hope for the development of new, more personalized therapies against cancer.

Source: prizrenpost